Indian Pharma’s 51% Sudan Import Share Drives New Investment Drive

For pharma executives, the 51% import share in Sudan is more than a dominance metric—it's a beachhead for deeper integration. As Ambassador Eltom invites investment, the opportunity extends beyond selling pills to establishing local production lines, streamlining regulatory approvals through direct engagement with Sudan's National Board of Pharmaceuticals and Poisons, and securing a captive market in a country that will depend on affordable generics for decades. The question now is which Indian firms will move first from exports to equity.

On July 12, 2026, a high-level roundtable in New Delhi marked a strategic pivot in Sudan's post-war recovery: a direct appeal to Indian pharmaceutical and healthcare companies to invest in the rebuilding of the nation's shattered health infrastructure. Sudanese Ambassador Mohammed Abdalla Ali Eltom underscored that Indian medicines already account for more than 51% of Sudan's total pharmaceutical imports, a commanding market share that Khartoum now seeks to leverage for deeper economic partnership beyond mere trade. The event, co-organized by the Embassy of Sudan and the India & Arab Countries Chamber of Commerce, Industry & Agriculture (IACCIA), assembled leading Indian pharmaceutical firms, while Sudan's National Board of Pharmaceuticals and Poisons and private sector representatives joined virtually. This gathering signals a deliberate shift from humanitarian aid dependency toward long-term commercial collaboration in one of Africa's most war-ravaged nations.

“

For pharma executives, the 51% import share in Sudan is more than a dominance metric—it's a beachhead for deeper integration.

The 51% import figure is not just a trade statistic; it embodies decades of trust built by Indian generics—affordable, quality-assured, and often the only accessible option for a country with a per capita health spend that is among the lowest globally. Sudan's civil war, which erupted in 2023 and devastated infrastructure across the country, has left healthcare facilities in ruins, disrupted supply chains, and exacerbated a massive burden of communicable and non-communicable diseases. Against this backdrop, IACCIA Secretary General (In-charge) Waiel Awwad stressed that pharmaceuticals and healthcare were chosen as priority sectors precisely because of the war's direct impact on public health. The roundtable is thus a pivotal moment: it transforms India's role from a distant supplier to a potential on-the-ground partner in reconstruction.

For Indian pharma companies—from major generics manufacturers to emerging biotech firms—this invitation opens a window to move up the value chain. Rather than simply shipping finished dosages, companies could explore local manufacturing, packaging, and distribution joint ventures, which would not only circumvent logistics challenges but also align with Sudan's likely preference for import substitution and job creation. The virtual presence of Sudan's pharmaceutical regulator suggests a willingness to streamline drug registration and quality certification, reducing barriers that have historically hindered market entry. If successful, such investments could lock in long-term supply contracts and brand loyalty in a population of 45 million, where the healthcare market is expected to grow as reconstruction funding and donor aid flow in.